Dr Mark Bloch

Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I, 2016, 'Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE', BMJ OPEN, vol. 6, http://dx.doi.org/10.1136/bmjopen-2016-012179

Lee FJ; Monteiro P; Baker D; Bloch M; Roth N; Finlayson R; Moore R; Hoy J; Martinez E; Carr A, 2016, 'Rosuvastatin vs. protease inhibitor switching for hypercholesterolaemia: a randomized trial', HIV Medicine, vol. 17, pp. 605 - 614, http://dx.doi.org/10.1111/hiv.12362

Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I, 2016, 'Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE', BMJ Open, vol. 6, http://dx.doi.org/10.1136/bmjopen-2016-012179

Lee FJ; Marriott D; Bloch M; Richardson R; Mackenzie N; Carr A, 2016, 'Post-prandial lipid effects of raltegravir versus darunavir/ritonavir in HIV-1-infected adults commencing combination ART', Journal of Antimicrobial Chemotherapy, vol. 71, pp. 1127 - 1129, http://dx.doi.org/10.1093/jac/dkv436

de Looze F; Russo M; Bloch M; Montgomery B; Shephard A; Smith G; Aspley S, 2016, 'Efficacy of flurbiprofen 8.75 mg spray in patients with sore throat due to an upper respiratory tract infection: A randomised controlled trial', European Journal of General Practice, vol. 22, pp. 111 - 118, http://dx.doi.org/10.3109/13814788.2016.1145650

Van Lunzen J; Antinori A; Cohen CJ; Arribas JR; Wohl DA; Rieger A; Rachlis A; Bloch M; Segal-Maurer S; Garner W, 2016, 'Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: Week 96 efficacy and safety from a randomized phase 3b study', AIDS, vol. 30, pp. 251 - 259, http://dx.doi.org/10.1097/QAD.0000000000000911

Hoehn KB; Gall A; Bashford-Rogers R; Fidler SJ; Kaye S; Weber JN; McClure MO; Kellam P; Pybus OG; Breckenridge A, 2015, 'Dynamics of immunoglobulin sequence diversity in HIV-1 infected individuals', Philosophical Transactions of the Royal Society B: Biological Sciences, vol. 370, http://dx.doi.org/10.1098/rstb.2014.0241

Abgrall S; Rachas A; Tourret J; Isnard-Bagnis C; Billaud E; Tattevin P; Costagliola D; Guiguet M; Durieux P; Abgrall S, 2015, 'A Multifaceted Intervention Designed to Improve Medical Management of Moderate to Advanced Chronic Kidney Disease in HIV-Infected Patients: A Cluster Randomized Trial', Clinical Infectious Diseases, vol. 61, pp. 375 - 384, http://dx.doi.org/10.1093/cid/civ310

Jarrin I; Pantazis N; Dalmau J; Phillips AN; Olson A; Mussini C; Boufassa F; Costagliola D; Porter K; Blanco J, 2015, 'Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4 + T-cell recovery once HIV-1 suppression is achieved?', AIDS, vol. 29, pp. 2323 - 2333, http://dx.doi.org/10.1097/QAD.0000000000000805

Murray DD; Suzuki K; Law M; Trebicka J; Neuhaus J; Wentworth D; Johnson M; Vjecha MJ; Kelleher AD; Emery S, 2015, 'Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study', PLoS ONE, vol. 10, http://dx.doi.org/10.1371/journal.pone.0139981

Templeton DJ; Wright ST; McManus H; Lawrence C; Russell DB; Law MG; Petoumenos K; Ellis D; Bloch M; Agrawal S, 2015, 'Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD)', BMC Infectious Diseases, vol. 15, http://dx.doi.org/10.1186/s12879-015-1051-4

Alavi M; Spelman T; Matthews GV; Haber PS; Day C; van Beek I; Walsh N; Yeung B; Bruneau J; Petoumenos K, 2015, 'Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C', International Journal of Drug Policy, http://dx.doi.org/10.1016/j.drugpo.2015.05.003

Wright ST; Law MG; Cooper DA; Keen P; McDonald A; Middleton M; Woolley I; Kelly M; Petoumenos K; Ellis D, 2015, 'Temporal trends of time to antiretroviral treatment initiation, interruption and modification: Examination of patients diagnosed with advanced HIV in Australia', Journal of the International AIDS Society, vol. 18, http://dx.doi.org/10.7448/IAS.18.1.19463

Han N; Wright ST; O'Connor CC; Hoy J; Ponnampalavanar S; Grotowski M; Zhao HX; Kamarulzaman A; Ellis D; Bloch M, 2015, 'HIV and aging: Insights from the Asia Pacific HIV Observational Database (APHOD)', HIV Medicine, vol. 16, pp. 152 - 160, http://dx.doi.org/10.1111/hiv.12188

Cohen C; Wohl D; Arribas JR; Henry K; Van Lunzen J; Bloch M; Towner W; Wilkins E; Ebrahimi R; Porter D, 2014, 'Week 48 results from a randomized clinical trial of rilpivirine/ emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/ tenofovir disoproxil fumarate in treatment-naive HIV-1-infecte', AIDS, vol. 28, pp. 989 - 997, http://dx.doi.org/10.1097/QAD.0000000000000169

Bieber T; Chosidow O; Bodsworth N; Tyring S; Hercogova J; Bloch M; Davis M; Lewis M; Boutolleau D; Attali P, 2014, 'Efficacy and safety of aciclovir mucoadhesive buccal tablet in immunocompetent patients with labial herpes (LIP trial): A double-blind, placebo-controlled, self-initiated trial', Journal of Drugs in Dermatology, vol. 13, pp. 791 - 798

Bloch M; Tong W; Lee F; Richardson R; Carr A; Hoy J; Baker D, 2014, 'Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks', HIV Medicine, http://dx.doi.org/10.1111/hiv.12123

Russo M; Bloch M; Looze FD; Morris C; Shephard A, 2013, 'Flurbiprofen microgranules for relief of sore throat: A randomised, double-blind trial', British Journal of General Practice, vol. 63, http://dx.doi.org/10.3399/bjgp13X663118

Raffi F; Rachlis A; Stellbrink HJ; Hardy WD; Torti C; Orkin C; Bloch M; Podzamczer D; Pokrovsky V; Pulido F, 2013, 'Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study', The Lancet, vol. 381, pp. 735 - 743, http://dx.doi.org/10.1016/S0140-6736(12)61853-4

Nelson MR; Elion RA; Cohen CJ; Mills A; Hodder SL; Segal-Maurer S; Bloch M; Garner W; Guyer B; Williams S, 2013, 'Rilpivirine versus efavirenz in hiv-1-infected subjects receiving emtricitabine/tenofovir df: Pooled 96-week data from ECHO and THRIVE studies', HIV Clinical Trials, vol. 14, pp. 81 - 91, http://dx.doi.org/10.1310/hct1403-81

Worm SW; Bower M; Reiss P; Bonnet F; Law M; Fätkenheuer G; d'Arminio Monforte A; Abrams DI; Grulich A; Fontas E, 2013, 'Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study', BMC Infectious Diseases, vol. 13, http://dx.doi.org/10.1186/1471-2334-13-471

Lee FJ; Amin J; Bloch M; Pett SL; Marriott D; Carr A, 2013, 'Skeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adults', Journal of Acquired Immune Deficiency Syndromes, vol. 62, pp. 525 - 533, http://dx.doi.org/10.1097/QAI.0b013e3182832578

Nelson M; Amaya G; Clumeck N; Arns da cunha C; Jayaweera D; Junod P; Li T; Tebas P; Stevens M; Buelens A, 2012, 'Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the phase III randomized, double-blind ECHO and THRIVE t', Journal of Antimicrobial Chemotherapy, vol. 67, pp. 2020 - 2028, http://dx.doi.org/10.1093/jac/dks130

Twiss J; McKenna SP; Bloch M; Bonney M, 2012, 'Erratum: Patient and clinician perceived benefit of early consumption of famciclovir for the treatment of herpes outbreaks. Value in Health (2011) 14:7 (A266))', Value in Health, vol. 15, pp. 789, http://dx.doi.org/10.1016/j.jval.2012.07.001

Schlesinger N; Alten RE; Bardin T; Schumacher HR; Bloch M; Gimona A; Krammer G; Murphy V; Richard D; So AK, 2012, 'Canakinumab for acute gouty arthritis in patients with limited treatment options: Results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions', Annals of the Rheumatic Diseases, vol. 71, pp. 1839 - 1848, http://dx.doi.org/10.1136/annrheumdis-2011-200908

Carey D; Pett SL; Bloch M; Wand H; MacRae K; Beileiter K; Ray JE; Boyd MA; Emery S; Cooper DA, 2012, 'A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults', Journal of Acquired Immune Deficiency Syndromes, vol. 60, pp. 143 - 149, http://dx.doi.org/10.1097/QAI.0b013e318252f97e

Haskelberg H; Hoy JF; Amin J; Ebeling PR; Emery S; Carr A; Allworth A; Anderson J; Baker D; Bloch M, 2012, 'Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine', PLoS ONE, vol. 7, http://dx.doi.org/10.1371/journal.pone.0038377

Alavi M; Grebely J; Matthews GV; Petoumenos K; Yeung B; Day C; Lloyd AR; Van Beek I; Kaldor JM; Hellard M, 2012, 'Effect of pegylated interferon-α-2a treatment on mental health during recent hepatitis C virus infection', Journal of Gastroenterology and Hepatology (Australia), vol. 27, pp. 957 - 965, http://dx.doi.org/10.1111/j.1440-1746.2011.07035.x

Bloch M; Farris M; Tilden D; Gowers A; Cunningham N, 2010, 'Triple-class HIV antiretroviral therapy failure in an Australian primary care setting', Sexual Health, vol. 7, pp. 17 - 24, http://dx.doi.org/10.1071/SH09039

Grebely J; Petoumenos K; Hellard M; Matthews GV; Suppiah V; Applegate T; Yeung B; Marks P; Rawlinson W; Lloyd AR, 2010, 'Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection', Hepatology, vol. 52, pp. 1216 - 1224, http://dx.doi.org/10.1002/hep.23850

Calmy A; Bloch M; Wand H; Delhumeau C; Finlayson R; Rafferty M; Norris R; Hirschel B; Cooper DA; Carr A, 2010, 'No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial', HIV Medicine, vol. 11, pp. 493 - 501, http://dx.doi.org/10.1111/j.1468-1293.2009.00817.x

Amin J; Martin A; Bloch M; Carr A, 2010, 'Reply to Landman and Soonawala', Clinical Infectious Diseases, vol. 50, pp. 1200 - 1201, http://dx.doi.org/10.1086/651469

Meads DM; McKenna SP; Bonney MA; Bloch MT, 2009, 'Further validation and responsiveness assessment of the herpes outbreak impact questionnaire and herpes symptom checklist', Value in Health, vol. 12, pp. 397 - 400, http://dx.doi.org/10.1111/j.1524-4733.2008.00450.x

Mitsuyasu RT; Merigan TC; Carr A; Zack JA; Winters MA; Workman C; Bloch M; Lalezari J; Becker S; Thornton L, 2009, 'Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34 ⁺ cells', Nature Medicine, vol. 15, pp. 285 - 292, http://dx.doi.org/10.1038/nm.1932

Martin A; Bloch M; Amin J; Baker D; Cooper DA; Emery S; Carr A, 2009, 'Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: A randomized, 96-week trial', Clinical Infectious Diseases, vol. 49, pp. 1591 - 1601, http://dx.doi.org/10.1086/644769

Bodsworth N; Bloch M; McNulty A; Denham I; Doong N; Trottier S; Adena M; Bonney MA; Agnew J; Abdurahman I, 2008, '2-Day versus 5-day famciclovir as treatment of recurrences of genital herpes: Results of the FaST study', Sexual Health, vol. 5, pp. 219 - 225, http://dx.doi.org/10.1071/SH08013

Bodsworth N; Bloch M; McNulty A; Denham I; Doong N; Trottier S; Adena M; Bonney MA; Agnew J; Abdurahman I, 2008, '2-Day versus 5-day famciclovir as treatment of recurrences of genital herpes: Results of the FaST study (Sexual Health (2008) 5, 3, (219-225))', Sexual Health, vol. 5, pp. 379, http://dx.doi.org/10.1071/SH08013_CO

Markowitz M; Nguyen BY; Gotuzzo E; Mendo F; Ratanasuwan W; Kovacs C; Prada G; Morales-Ramirez JO; Crumpacker CS; Isaacs RD, 2007, 'Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: Results of a 48-week controlled st', Journal of Acquired Immune Deficiency Syndromes, vol. 46, pp. 125 - 133, http://dx.doi.org/10.1097/QAI.0b013e318157131c

Emery S; Kelleher AD; Workman C; Puls RL; Bloch M; Baker D; Anderson J; Hoy J; Ip S; Nalliah K, 2007, 'Influence of IFNγ co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy', Human Vaccines, vol. 3, pp. 260 - 267

Fox Z; Antunes F; Davey R; Gazzard B; Klimas N; Labriola A; Losso M; Neaton JD; Phillips A; Ruxrungtham K, 2007, 'Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count ≥ 300 cells/μL who were assigned to 7.5 MIU interleukin-2', HIV Medicine, vol. 8, pp. 112 - 123, http://dx.doi.org/10.1111/j.1468-1293.2007.00440.x

Gold J; Batterham MJ; Rekers H; Harms MK; Geurts TBP; Helmyr PME; Silva de Mendonça J; Carvalho LHF; Panos G; Pinchera A, 2006, 'Effects of nandrolone decanoate compared with placebo or testosterone on HIV-associated wasting', HIV Medicine, vol. 7, pp. 146 - 155, http://dx.doi.org/10.1111/j.1468-1293.2006.00358.x

Bloch MT; Smith DE; Quan D; Kaldor JM; Zaunders JJ; Petoumenos K; Irvine K; Law M; Grey P; Finlayson RJ, 2006, 'The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: Final results from a randomized clinical trial (pulse)', Journal of Acquired Immune Deficiency Syndromes, vol. 42, pp. 192 - 202, http://dx.doi.org/10.1097/01.qai.0000219779.50668.e6

Pett SL; Wand H; Law MG; Arduino R; Lopez JC; Knysz B; Pereira LC; Pollack S; Reiss P; Tambussi G, 2006, 'Evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial (ESPRIT): Geographical and gender differences in the baseline characteristics of participants', HIV Clinical Trials, vol. 7, pp. 70 - 85, http://dx.doi.org/10.1310/4733-ACQF-F3P4-2QAC

Ray JE; Marriott D; Bloch MT; McLachlan AJ, 2005, 'Therapeutic drug monitoring of atazanavir: Surveillance of pharmacotherapy in the clinic', British Journal of Clinical Pharmacology, vol. 60, pp. 291 - 299, http://dx.doi.org/10.1111/j.1365-2125.2005.02413.x

Kinloch-De Loes S; Hoen B; Smith DE; Autran B; Lampe FC; Phillips AN; Goh LE; Andersson J; Tsoukas C; Sonnerborg A, 2005, 'Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection', Journal of Infectious Diseases, vol. 192, pp. 607 - 617, http://dx.doi.org/10.1086/432002

Winston A; Bloch M; Carr A; Amin J; Mallon PWG; Ray J; Marriott D; Cooper DA; Emery S, 2005, 'Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy', Journal of Antimicrobial Chemotherapy, vol. 56, pp. 380 - 387, http://dx.doi.org/10.1093/jac/dki235

Van Leth F; Phanuphak P; Stroes E; Gazzard B; Cahn P; Raffi F; Wood R; Bloch M; Katlama C; Kastelein JJP, 2004, 'Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1', PLoS Medicine, vol. 1, pp. 064 - 074, http://dx.doi.org/10.1371/journal.pmed.0010019

Martin A; Smith D; Carr A; Hoy J; Chuah J; Mallal S; Law M; Clements M; Cooper DA; Macrae K, 2004, 'Progression of lipodystrophy (LD) with continued thymidine analogue usage: Long-term follow-up from a randomized clinical trial (the PIILR study)', HIV Clinical Trials, vol. 5, pp. 192 - 200, http://dx.doi.org/10.1310/0GU7-6X27-MMHE-5ALE

Kaufmann GR; Bloch M; Finlayson R; Zaunders J; Smith D; Cooper DA, 2002, 'The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy', AIDS, vol. 16, pp. 359 - 367, http://dx.doi.org/10.1097/00002030-200202150-00007

Stewart GJ; Ashton LJ; Biti RA; Ffrench RA; Bennetts BH; Newcombe NR; Benson EM; Carr A; Cooper DA; Kaldor JM, 1997, 'Increased frequency of CCR-5 Δ32 heterozygotes among long-term non-progressors with HIV-1 infection', AIDS, vol. 11, pp. 1833 - 1838